查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595584

預防藥物市場：按分銷管道、按專業分類 - 2025-2030 年全球預測

Preventive Medicines Market by Distribution Channels (Diagnostic Centers, Hospitals), Specialty Areas (Aerospace Medicine, General Preventive Medicine, Occupational Medicine) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年預防藥物市場價值為3,764.9億美元，預計2024年將達到4,075.8億美元，複合年成長率為8.74%，到2030年將達到6,769.8億美元。

預防藥物包括旨在預防疾病的各種藥物、疫苗、補充品和生活方式干涉措施。由於慢性病的流行、醫療費用的上升以及健康意識的增強，對預防性醫療保健的需求不斷增加。最終用途涵蓋感染疾病、慢性病管理、癌症預防、婦幼保健等，包括醫院、診所、研究機構和直接面對消費者的平台。該市場是由診斷技術的進步、醫療保健基礎設施投資的增加以及遠距遠端醫療的日益普及等關鍵因素推動的。成長潛力在於免疫計畫的擴大、用於自我監測的穿戴式技術的普及以及人工智慧與個人化預防策略的整合。

主要市場統計
基準年[2023] 3764.9億美元
預測年份 [2024] 4075.8億美元
預測年份 [2030] 6769.8億美元
複合年成長率（%） 8.74%

新興市場的最新機會包括開發針對新興病原體的針對性疫苗、針對遺傳特徵量身定做的營養食品以及提供即時健康資料的行動醫療應用程式。公司可以透過投資研究和擴展其數位健康能力來利用這些優勢。然而，監管障礙、高昂的研發成本和疫苗猶豫等挑戰可能會阻礙成長。此外，低收入地區預防藥物的供應和負擔能力仍然是一個主要障礙。儘管有這些挑戰，適合開拓的創新領域包括用於疾病預測的生物資訊學、植物來源疫苗以及應用 CRISPR 技術預防遺傳疾病。

從策略上講，公司將重點關注與高科技公司的合作，以加強精準醫療舉措，參與官民合作關係關係，以擴大對服務不足的市場的覆蓋範圍，並追求科學突破，以保持在研究的前沿。市場的性質是動態和競爭的，重點轉向預防措施，不僅減少發病率，而且促進整體醫療保健。成功應對這些複雜因素、利用新技術並促進跨行業合作的公司將能夠確保這個不斷發展的行業的持續成長。

市場動態：揭示快速發展的預防藥物市場的關鍵市場洞察

供需的動態交互作用正在改變預防醫學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 藥品、醫療設備、治療和手術的價格上漲
    • 製藥公司對生產預防藥物的興趣增加
    • 傳播預防醫學教育的措施和活動
  • 市場限制因素
    • 預防藥物區域確認緩慢
  • 市場機會
    • 協作市場生態系統
    • 支持客製化處方箋的技術進步
  • 市場挑戰
    • 缺乏引用預防藥物的確切證據或研究

波特五力：駕馭預防藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解預防醫學市場的外部影響

外部宏觀環境因素在塑造預防藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解預防醫學市場的競爭狀況

對預防藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣預防藥物市場供應商的績效評估

FPNV定位矩陣是評估預防藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了預防藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，預防藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 藥品、醫療設備、治療和手術的價格上漲
      • 製藥公司對生產預防藥物的興趣增加
      • 傳播預防醫學教育的措施和活動
    • 抑制因素
      • 預防性藥物的鬆散區域檢查
    • 機會
      • 協作市場生態系統
      • 技術進步支援制定客製化解決方案
    • 任務
      • 沒有經過證實的證據或研究支持預防醫學。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依分銷管道分類的預防藥品市場

  • 診斷中心
  • 醫院

第7章 預防醫學專業市場

  • 航太醫學
  • 綜合預防醫學
  • 工業醫學
  • 公共衛生

第8章美洲預防醫學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區預防醫學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲預防醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aetna Inc.
  • Affymetrix, Inc
  • Cancer Prevention Pharmaceuticals, Inc
  • Dilon Technologies, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • McKesson Corporation
  • Medtronic PLC
  • Merck & Co. Inc.
  • Myriad Genetics, Inc.
  • Myriad Women's Health, Inc.
  • Novo Nordisk A\S
  • Omada Health, Inc.
  • Omnicell, Inc.
  • Pfizer, Inc.
Product Code: MRR-031C6D6EB1CD

The Preventive Medicines Market was valued at USD 376.49 billion in 2023, expected to reach USD 407.58 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 676.98 billion by 2030.

Preventive medicines encompass a broad range of pharmaceuticals, vaccines, supplements, and lifestyle interventions aimed at preventing diseases before they occur. The growing necessity for preventive healthcare is driven by rising chronic disease prevalence, increasing healthcare costs, and heightened awareness around health and wellness. Its application spans across infectious diseases, chronic disease management, cancer prevention, and maternal-child health, with end-use scope including hospitals, clinics, research institutes, and direct-to-consumer platforms. The market is propelled by key factors such as technological advancements in diagnostics, increased investment in healthcare infrastructure, and the growing implementation of telemedicine. Growth potential lies in expanding immunization programs, the proliferation of wearable tech for self-monitoring, and the integration of AI in personalized preventive strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 376.49 billion
Estimated Year [2024] USD 407.58 billion
Forecast Year [2030] USD 676.98 billion
CAGR (%) 8.74%

Latest opportunities in the market include developing targeted vaccines for emerging pathogens, nutraceuticals tailored to genetic profiles, and mobile health applications that offer real-time health data. Companies can capitalize on these by investing in research and expanding their digital health capabilities. However, challenges such as regulatory hurdles, high R&D costs, and vaccine hesitancy can impede growth. Furthermore, the accessibility and affordability of preventive medicines in low-income regions remain significant barriers. Despite these challenges, innovation areas ripe for exploration include bioinformatics for disease prediction, plant-based vaccines, and CRISPR technology applications for hereditary disease prevention.

Strategically, businesses should focus on collaborations with tech firms to enhance precision medicine initiatives, engage in public-private partnerships to improve reach in underserved markets, and continuously invest in research to stay at the forefront of scientific breakthroughs. The nature of the market is dynamic and competitive, with emphasis shifting towards preventive measures that not only reduce incidence rates but also promote holistic health management. Companies that successfully navigate these complex factors, leveraging emerging technologies and fostering cross-industry collaborations, will likely secure sustainable growth in this evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preventive Medicines Market

The Preventive Medicines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prices of medicines, medical devices, medical treatments, and surgical procedures
    • Increasing interest of pharma companies in manufacturing of preventive medicine
    • Initiatives and events to spread education about the preventive medicines
  • Market Restraints
    • Loosely defined regional confirmations referring to preventive drug
  • Market Opportunities
    • Collaborative market ecosystem
    • Technology advancement to support prescription of tailor made solutions
  • Market Challenges
    • Absence of proven evidences or studies citing preventive medicine

Porter's Five Forces: A Strategic Tool for Navigating the Preventive Medicines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preventive Medicines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preventive Medicines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preventive Medicines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preventive Medicines Market

A detailed market share analysis in the Preventive Medicines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preventive Medicines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preventive Medicines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Preventive Medicines Market

A strategic analysis of the Preventive Medicines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preventive Medicines Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Affymetrix, Inc, Cancer Prevention Pharmaceuticals, Inc, Dilon Technologies, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Inc., Myriad Women's Health, Inc., Novo Nordisk A\S, Omada Health, Inc., Omnicell, Inc., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Preventive Medicines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Distribution Channels, market is studied across Diagnostic Centers and Hospitals.
  • Based on Specialty Areas, market is studied across Aerospace Medicine, General Preventive Medicine, Occupational Medicine, and Public Health.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prices of medicines, medical devices, medical treatments, and surgical procedures
      • 5.1.1.2. Increasing interest of pharma companies in manufacturing of preventive medicine
      • 5.1.1.3. Initiatives and events to spread education about the preventive medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Loosely defined regional confirmations referring to preventive drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative market ecosystem
      • 5.1.3.2. Technology advancement to support prescription of tailor made solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Absence of proven evidences or studies citing preventive medicine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preventive Medicines Market, by Distribution Channels

  • 6.1. Introduction
  • 6.2. Diagnostic Centers
  • 6.3. Hospitals

7. Preventive Medicines Market, by Specialty Areas

  • 7.1. Introduction
  • 7.2. Aerospace Medicine
  • 7.3. General Preventive Medicine
  • 7.4. Occupational Medicine
  • 7.5. Public Health

8. Americas Preventive Medicines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Preventive Medicines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Preventive Medicines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetna Inc.
  • 2. Affymetrix, Inc
  • 3. Cancer Prevention Pharmaceuticals, Inc
  • 4. Dilon Technologies, Inc.
  • 5. Eli Lilly and Company
  • 6. GlaxoSmithKline PLC
  • 7. McKesson Corporation
  • 8. Medtronic PLC
  • 9. Merck & Co. Inc.
  • 10. Myriad Genetics, Inc.
  • 11. Myriad Women's Health, Inc.
  • 12. Novo Nordisk A\S
  • 13. Omada Health, Inc.
  • 14. Omnicell, Inc.
  • 15. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. PREVENTIVE MEDICINES MARKET RESEARCH PROCESS
  • FIGURE 2. PREVENTIVE MEDICINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREVENTIVE MEDICINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREVENTIVE MEDICINES MARKET DYNAMICS
  • TABLE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY AEROSPACE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GENERAL PREVENTIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY OCCUPATIONAL MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PUBLIC HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 101. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023